Literature DB >> 2649227

Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry.

H J Helin1, M J Helle, O P Kallioniemi, J J Isola.   

Abstract

Human breast carcinomas (n = 232) were evaluated for estrogen and progesterone receptors (ER, PR) by immunohistochemical study and by cytosol steroid-binding assay (n = 185). The staining was scored (histoscore) by estimates of relative nuclear staining intensity and the percentage of positively stained carcinoma cells. Of the invasive ductal carcinomas 72% were ER-positive and 55% were PR-positive. The invasive lobular, intraductal, tubular, and mucinous carcinomas were the most frequent ER-positive tumor types, whereas comedo and medullary carcinomas only rarely contained ER. Progesterone receptor was most frequently present in intraductal, tubular, and mucinous carcinomas. Better differentiated tumors with lower histologic grade were significantly associated with high prevalence of immunohistochemically determined ER and PR (P less than 0.0001). Proliferative cell fraction, determined by DNA flow cytometric study (n = 63), was inversely related to ER (P = 0.03) and PR (P = 0.05) status. Aneuploidy was independent of ER or PR content.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649227     DOI: 10.1002/1097-0142(19900501)63:9<1761::aid-cncr2820630918>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Multicentric Breast Carcinoma: Evaluation of Clinicopathological and Immunohistochemical Characteristics.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

2.  Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma.

Authors:  S Soomro; S Shousha
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

3.  Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.

Authors:  J H Lagendijk; H Mullink; P J van Diest; G A Meijer; C J Meijer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 4.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

5.  Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.

Authors:  S Aaltomaa; P Lipponen; S Papinaho; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.

Authors:  C R Wenger; S Beardslee; M A Owens; G Pounds; T Oldaker; P Vendely; M R Pandian; D Harrington; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

7.  Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States).

Authors:  C Schairer; C Byrne; P M Keyl; L A Brinton; S R Sturgeon; R N Hoover
Journal:  Cancer Causes Control       Date:  1994-11       Impact factor: 2.506

8.  The relationship of estrogen receptor status to DNA ploidy in breast cancer.

Authors:  A Tsuchiya; M Nihei; Y Ando; S Suzuki; I Kimijima; R Abe
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

9.  Triple-negative breast cancer and obesity in a rural Appalachian population.

Authors:  Linda Vona-Davis; David P Rose; Hannah Hazard; Marissa Howard-McNatt; Farrell Adkins; Jessica Partin; Gerald Hobbs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

10.  Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer.

Authors:  Hela Masmoudi; Stephen M Hewitt; Nicholas Petrick; Kyle J Myers; Marios A Gavrielides
Journal:  IEEE Trans Med Imaging       Date:  2009-01-19       Impact factor: 10.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.